Cargando…
Cost-utility analysis of a universal pneumococcal vaccination programme for older adults in Norway
The aim of this study was to establish whether a universal pneumococcal vaccination for older adults in Norway is likely to be cost-effective from the perspective of the health care provider. A decision tree model developed by the Public Health Agency of Sweden was adopted to the Norwegian setting....
Autores principales: | Nymark, Liv Solvår, Dag Berild, Jacob, Lyngstad, Trude Marie, Askeland Winje, Brita, Frimann Vestrheim, Didrik, Aaberge, Ingeborg, Juvet, Lene Kristine, Wolff, Ellen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746426/ https://www.ncbi.nlm.nih.gov/pubmed/35917277 http://dx.doi.org/10.1080/21645515.2022.2101333 |
Ejemplares similares
-
The Risk of Invasive Pneumococcal Disease Differs between Risk Groups in Norway Following Widespread Use of the 13-Valent Pneumococcal Vaccine in Children
por: Winje, Brita Askeland, et al.
Publicado: (2021) -
A Systematic Review of Studies Published between 2016 and 2019 on the Effectiveness and Efficacy of Pneumococcal Vaccination on Pneumonia and Invasive Pneumococcal Disease in an Elderly Population
por: Berild, Jacob Dag, et al.
Publicado: (2020) -
Gastrointestinal symptoms in invasive pneumococcal disease: a cohort study
por: Floeystad, Hans Kristian, et al.
Publicado: (2020) -
The 15-valent pneumococcal conjugate vaccine V114 induces cross-reactive antibodies against pneumococcal serotype 6C
por: Shi, Yaru, et al.
Publicado: (2023) -
Safety and immunogenicity of a multivalent pneumococcal conjugate vaccine given with 13-valent pneumococcal conjugate vaccine in healthy infants: A phase 2 randomized trial
por: Simon, Michael W., et al.
Publicado: (2023)